FGFR
8 drugsFibroblast Growth Factor Receptor
Predictive biomarker for patient selection in 17 indications
Understanding FGFR
What it means: FGFR alterations include fusions, amplifications, and mutations across FGFR1-4. Common in bladder, breast, and cholangiocarcinoma.
Why it matters: FGFR inhibitors (erdafitinib, pemigatinib, futibatinib) target FGFR-altered cancers with good response rates.
Testing: Tested via NGS to identify fusions, mutations, and amplifications across FGFR1-4 genes.
8
Approved Drugs
17
Indications
8
Companies
FGFR is a precision-medicine biomarker linked to 8 FDA-approved targeted drugs from 8 companies, spanning 17 indications including Renal Cell Carcinoma, Soft Tissue Sarcoma, Idiopathic Pulmonary Fibrosis. Explore the targeted therapies, indications, testing methods, and companies developing FGFR drugs below.
Search FGFR Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting FGFR
FGFR Indications
Renal Cell Carcinoma Soft Tissue Sarcoma Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Systemic Sclerosis-Associated Interstitial Lung Disease Metastatic RET fusion-positive non-small cell lung cancer Advanced or metastatic RET fusion-positive thyroid cancer Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Advanced renal cell carcinoma Advanced soft tissue sarcoma Metastatic colorectal cancer Locally advanced, unresectable or metastatic gastrointestinal stromal tumor Hepatocellular carcinoma Cholangiocarcinoma Myeloid/Lymphoid Neoplasms Urothelial Carcinoma